Cargando…

Development and validation of machine learning models to predict survival of patients with resected stage-III NSCLC

OBJECTIVE: To compare the performance of three machine learning algorithms with the tumor, node, and metastasis (TNM) staging system in survival prediction and validate the individual adjuvant treatment recommendations plan based on the optimal model. METHODS: In this study, we trained three machine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Long, Zhao, Qifan, Fu, Shenbo, Cao, Fei, Hou, Bin, Ma, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040845/ https://www.ncbi.nlm.nih.gov/pubmed/36994203 http://dx.doi.org/10.3389/fonc.2023.1092478

Ejemplares similares

Development and External Validation of a Nomogram to Predict Recurrence-Free Survival After R0 Resection for Stage II/III Gastric Cancer: An International Multicenter Study
por: Lu, Jun, et al.
Publicado: (2020)

Survival after wedge resection versus lobectomy for stage IA second primary NSCLC with previous lung cancer-directed surgery
por: Song, Congkuan, et al.
Publicado: (2022)

Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
por: Shang, Shijie, et al.
Publicado: (2022)

Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients
por: Gao, Fei, et al.
Publicado: (2020)

Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC
por: Gallina, Filippo Tommaso, et al.
Publicado: (2023)

The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada
por: Beers, Craig A., et al.
Publicado: (2023)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Development and Validation of Nomogram for Predicting Survival of Primary Liver Cancers Using Machine Learning
por: Chen, Rui, et al.
Publicado: (2022)

High-dose concurrent chemo–proton therapy for Stage III NSCLC: preliminary results of a Phase II study
por: Oshiro, Yoshiko, et al.
Publicado: (2014)

Development and Validation of a CT-Based Radiomics Nomogram for Predicting Postoperative Progression-Free Survival in Stage I–III Renal Cell Carcinoma
por: Zhang, Haijie, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
por: Haslett, Kate, et al.
Publicado: (2016)

High-Grade Inflammation Attenuates Chemosensitivity and Confers to Poor Survival of Surgical Stage III CRC Patients
por: Ying, Hou-Qun, et al.
Publicado: (2021)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection
por: Huang, Yao, et al.
Publicado: (2021)

Vitamin D Status and Survival in Stage II-III Colorectal Cancer
por: Bao, Yichao, et al.
Publicado: (2020)

Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer
por: Li, Di, et al.
Publicado: (2021)

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022)

Machine learning based prognostic model of Chinese medicine affecting the recurrence and metastasis of I-III stage colorectal cancer: A retrospective study in China
por: Tang, Mo, et al.
Publicado: (2022)

Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients
por: Li, Chang, et al.
Publicado: (2022)

Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching’s Study
por: Zhang, Bo, et al.
Publicado: (2021)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha
por: Moschella, Federica, et al.
Publicado: (2023)

Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual
por: Wu, Lei-Lei, et al.
Publicado: (2020)

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
por: Zuo, Zhichao, et al.
Publicado: (2022)

Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma
por: Li, Zefeng, et al.
Publicado: (2022)

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

Development and validation of a machine learning model for survival risk stratification after esophageal cancer surgery
por: Xu, Jinye, et al.
Publicado: (2022)

Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Lei, Tianyu, et al.
Publicado: (2021)

Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database
por: Wang, Yan-qing, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

A Novel Staging System to Forecast the Cancer-Specific Survival of Patients With Resected Gallbladder Cancer
por: Yan, Yongcong, et al.
Publicado: (2020)

Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
por: You, Weiqiang, et al.
Publicado: (2022)

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
por: Han, Xiaohong, et al.
Publicado: (2019)

Efficacy of Chemotherapy in Survival of Stage I Nasopharyngeal Carcinoma
por: Ma, Jia-Lin, et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Impact of examined lymph node number on accurate nodal staging and long-term survival of resected Siewert type II-III adenocarcinoma of the esophagogastric junction: A large population-based study
por: Ding, Baicheng, et al.
Publicado: (2022)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uo20hotln4q06qs6k1jukfcqo8